Brief: UK's MHRA Approves Zanidatamab For Treatment Of Biliary Tract Cancer
19/02/2026 14:28
Feb 19 (Reuters) - MHRA: UK'S MHRA: APPROVES ZANIDATAMAB (ZIIHERA) FOR THE TREATMENT OF BILIARY TRACT CANCER ((Reuters.Briefs@thomsonreuters.com))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032